Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0510 Transporter Info
Gene Name KCNH2
Transporter Name Voltage-gated potassium channel Kv11.1
Gene ID
3757
UniProt ID
Q12809
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Maraviroc

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Maraviroc inhibits the transportation of Dofetilide by KCNH2 [4]

Affected Drug/Substrate

 Dofetilide Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  DT Modulation 2

 Maraviroc inhibits the activity of KCNH2 [5]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Pimozide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pimozide inhibits the activity of KCNH2 [6]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Thioridazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Thioridazine inhibits the activity of KCNH2 [6]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Bepridil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bepridil inhibits the activity of KCNH2 [6] , [7]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Haloperidol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Haloperidol inhibits the activity of KCNH2 [6] , [8]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Dofetilide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dofetilide inhibits the activity of KCNH2 [7]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Clozapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clozapine inhibits the activity of KCNH2 [7] , [8] , [9]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Risperidone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Risperidone inhibits the activity of KCNH2 [8]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Aripiprazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aripiprazole inhibits the activity of KCNH2 [8] , [9]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Olanzapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Olanzapine inhibits the activity of KCNH2 [8] , [9]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Mizolastine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mizolastine inhibits the activity of KCNH2 [10]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Fexofenadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fexofenadine inhibits the activity of KCNH2 [2]

  Erythromycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Erythromycin inhibits the activity of KCNH2 [11] , [12]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Quinine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinine inhibits the activity of KCNH2 [13]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Rofecoxib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rofecoxib inhibits the activity of KCNH2 [13]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Tegaserod

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tegaserod inhibits the activity of KCNH2 [14] , [15]

Cell System

 Chinese hamster ovary (CHO) cells-KCNH2

  Levofloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Levofloxacin inhibits the activity of KCNH2 [16]

Cell System

 Chinese hamster ovary (CHO) cells-KCNH2

  Moxifloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Moxifloxacin inhibits the activity of KCNH2 [16]

Cell System

 Chinese hamster ovary (CHO) cells-KCNH2

  Chloroquine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chloroquine inhibits the activity of KCNH2 [17]

Cell System

 Chinese hamster ovary (CHO) cells-KCNH2

  Halofantrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Halofantrine inhibits the activity of KCNH2 [17]

Cell System

 Chinese hamster ovary (CHO) cells-KCNH2

  Cisapride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisapride inhibits the activity of KCNH2 [18]

Cell System

 Chinese hamster ovary (CHO) cells-KCNH2

  Pentobarbital

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pentobarbital inhibits the activity of KCNH2 [32]

  Probucol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Probucol inhibits the activity of KCNH2 [33]

  Dronedarone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dronedarone inhibits the activity of KCNH2 [34]

  Metoclopramide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Metoclopramide inhibits the activity of KCNH2 [35]

  Gabapentin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Gabapentin inhibits the activity of KCNH2 [36]

  Lamotrigine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lamotrigine inhibits the activity of KCNH2 [36]

  Topiramate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Topiramate inhibits the activity of KCNH2 [36]

  Carmustine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carmustine inhibits the expression of KCNH2 [37]

  Lovastatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lovastatin affects the activity of KCNH2 [38]

  Metoprolol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Metoprolol inhibits the activity of KCNH2 [39]

  Mesoridazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mesoridazine inhibits the activity of KCNH2 [40]

  Dipyridamole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dipyridamole inhibits the activity of KCNH2 [41]

  Ketoconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ketoconazole inhibits the activity of KCNH2 [42]

  Arsenic

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Arsenic affects the expression of KCNH2 [43]

  Codeine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Codeine inhibits the activity of KCNH2 [44]

  Dextromethorphan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dextromethorphan inhibits the activity of KCNH2 [44]

  Hydroxyzine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hydroxyzine inhibits the activity of KCNH2 [45]

  Digoxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Digoxin inhibits the expression of KCNH2 [46]

  Ouabain

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ouabain inhibits the expression of KCNH2 [46]

  Chlorpheniramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorpheniramine inhibits the activity of KCNH2 [47]

  Dalfampridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dalfampridine inhibits the activity of KCNH2 [48]

  Amantadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amantadine inhibits the activity of KCNH2 [49]

  Grepafloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Grepafloxacin inhibits the activity of KCNH2 [49]

  Venlafaxine Hydrochloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Venlafaxine Hydrochloride inhibits the activity of KCNH2 [49]

  Econazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Econazole inhibits the activity of KCNH2 [50]

  Calcitriol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Calcitriol increases the expression of KCNH2 [51]

  Testosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Testosterone increases the expression of KCNH2 [51]

  Arsenic Trioxide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Arsenic Trioxide inhibits the expression of KCNH2 [52]

  Crizotinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Crizotinib inhibits the activity of KCNH2 [53]

  Clarithromycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clarithromycin inhibits the activity of KCNH2 [54]

  Flecainide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Flecainide inhibits the activity of KCNH2 [54]

  Fluvoxamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluvoxamine inhibits the activity of KCNH2 [54]

  Glyburide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Glyburide inhibits the activity of KCNH2 [54]

  Idarubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Idarubicin inhibits the activity of KCNH2 [54]

  Imipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imipramine inhibits the activity of KCNH2 [54]

  Lidocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lidocaine inhibits the activity of KCNH2 [54]

  Mexiletine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mexiletine inhibits the activity of KCNH2 [54]

  Phentolamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phentolamine inhibits the activity of KCNH2 [54]

  Ranolazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ranolazine inhibits the activity of KCNH2 [54]

  Tacrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tacrine inhibits the activity of KCNH2 [54]

  Tolcapone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tolcapone inhibits the activity of KCNH2 [54]

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisplatin inhibits the expression of KCNH2 [55]

  Azelastine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Azelastine inhibits the activity of KCNH2 [56]

  Benzatropine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzatropine inhibits the activity of KCNH2 [56]

  Cefotetan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefotetan inhibits the activity of KCNH2 [56]

  Cepharanthine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cepharanthine inhibits the activity of KCNH2 [56]

  Chlorprothixene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorprothixene inhibits the activity of KCNH2 [56]

  Clemastine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clemastine inhibits the activity of KCNH2 [56]

  Clofazimine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clofazimine inhibits the activity of KCNH2 [56]

  Clotrimazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clotrimazole inhibits the activity of KCNH2 [56]

  Diphenylpyraline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diphenylpyraline inhibits the activity of KCNH2 [56]

  Duloxetine Hydrochloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Duloxetine Hydrochloride inhibits the activity of KCNH2 [56]

  Dutasteride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dutasteride inhibits the activity of KCNH2 [56]

  Eletriptan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Eletriptan inhibits the activity of KCNH2 [56]

  Epinastine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Epinastine inhibits the activity of KCNH2 [56]

  Fentanyl

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fentanyl inhibits the activity of KCNH2 [56]

  Fluorescein

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluorescein inhibits the activity of KCNH2 [56]

  Flurazepam

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Flurazepam inhibits the activity of KCNH2 [56]

  Miconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Miconazole inhibits the activity of KCNH2 [56]

  Oxiconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oxiconazole inhibits the activity of KCNH2 [56]

  Palonosetron

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Palonosetron inhibits the activity of KCNH2 [56]

  Perphenazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Perphenazine inhibits the activity of KCNH2 [56]

  Promazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Promazine inhibits the activity of KCNH2 [56]

  Pyrithione zinc

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrithione zinc inhibits the activity of KCNH2 [56]

  Quetiapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quetiapine inhibits the activity of KCNH2 [56]

  Rescinnamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rescinnamine inhibits the activity of KCNH2 [56]

  Rosuvastatin Calcium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rosuvastatin Calcium inhibits the activity of KCNH2 [56]

  Rotigotine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rotigotine inhibits the activity of KCNH2 [56]

  Salmeterol Xinafoate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Salmeterol Xinafoate inhibits the activity of KCNH2 [56]

  Semaxanib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Semaxanib inhibits the activity of KCNH2 [56]

  Sertraline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sertraline inhibits the activity of KCNH2 [56]

  Sorafenib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sorafenib inhibits the activity of KCNH2 [56]

  Tazarotene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tazarotene inhibits the activity of KCNH2 [56]

  Terconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Terconazole inhibits the activity of KCNH2 [56]

  Toremifene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Toremifene inhibits the activity of KCNH2 [56]

  Triclabendazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triclabendazole inhibits the activity of KCNH2 [56]

  Triflupromazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triflupromazine inhibits the activity of KCNH2 [56]

  Triprolidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triprolidine inhibits the activity of KCNH2 [56]

  Ziprasidone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ziprasidone inhibits the activity of KCNH2 [56]

  Erlotinib Hydrochloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Erlotinib Hydrochloride inhibits the activity of KCNH2 [57]

  Fluoxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluoxetine inhibits the expression of KCNH2 [57]

  Imatinib Mesylate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imatinib Mesylate inhibits the activity of KCNH2 [57]

  Nilotinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nilotinib inhibits the expression of KCNH2 [57]

  Vandetanib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vandetanib inhibits the expression of KCNH2 [57]

  Amiodarone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amiodarone inhibits the activity of KCNH2 [54]

  Loratadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Loratadine inhibits the activity of KCNH2 [58]

  Carvedilol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carvedilol inhibits the activity of KCNH2 [39]

  Quinidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinidine inhibits the activity of KCNH2 [56]

  Chlorpromazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorpromazine inhibits the activity of KCNH2 [54]

  Verapamil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Verapamil inhibits the activity of KCNH2 [59]

  Trazodone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Trazodone inhibits the activity of KCNH2 [56]

  Tretinoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tretinoin inhibits the expression of KCNH2 [60]

  Sotalol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sotalol inhibits the activity of KCNH2 [59]

  Droperidol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Droperidol inhibits the activity of KCNH2 [56]

  Disopyramide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Disopyramide inhibits the activity of KCNH2 [56]

  Desipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desipramine inhibits the activity of KCNH2 [54]

  Reserpine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Reserpine inhibits the activity of KCNH2 [56]

  Tamoxifen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tamoxifen inhibits the activity of KCNH2 [56]

  Sunitinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sunitinib inhibits the activity of KCNH2 [54]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid increases the expression of KCNH2 [61]

  Nefazodone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nefazodone inhibits the activity of KCNH2 [56]

  Daunorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Daunorubicin inhibits the expression of KCNH2 [62]

  Mitoxantrone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mitoxantrone inhibits the expression of KCNH2 [62]

  Doxorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Doxorubicin inhibits the expression of KCNH2 [63]

  Desloratadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desloratadine inhibits the activity of KCNH2 [58]

  Ciprofloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ciprofloxacin inhibits the activity of KCNH2 [64] , [65]

  Linagliptin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Linagliptin inhibits the activity of KCNH2 [66]

  Betrixaban

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Betrixaban inhibits the activity of KCNH2 [67]

  Bicalutamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bicalutamide inhibits the activity of KCNH2 [68]

  Ximelegatran

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ximelegatran inhibits the activity of KCNH2 [69]

  Gemifloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Gemifloxacin inhibits the activity of KCNH2 [65]

  Linezolid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Linezolid inhibits the activity of KCNH2 [65]

  Vancomycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vancomycin inhibits the activity of KCNH2 [65]

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat inhibits the activity of KCNH2 [70]

  Propafenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Propafenone inhibits the activity of KCNH2 [71]

  Modafinil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Modafinil inhibits the activity of KCNH2 [72]

  Phenytoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenytoin inhibits the activity of KCNH2 [73]

  Mefloquine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mefloquine inhibits the activity of KCNH2 [74]

  Pentamidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pentamidine inhibits the activity of KCNH2 [75]

Drug Marketed but not Approved by US FDA

  Rotenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rotenone inhibits the activity of KCNH2 [54]

  Ebastine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ebastine inhibits the activity of KCNH2 [56]

  Profenamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Profenamine inhibits the activity of KCNH2 [56]

  Thonzonium bromide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Thonzonium bromide inhibits the activity of KCNH2 [56]

Drug in Phase 4 Trial

  Dihydrotestosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dihydrotestosterone inhibits the activity of KCNH2 [96]

Drug in Phase 3 Trial

  Volinanserin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Volinanserin inhibits the activity of KCNH2 [19] , [20]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Litoxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Litoxetine inhibits the activity of KCNH2 [27]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  BMS-927711

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 BMS-927711 inhibits the activity of KCNH2 [28]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Tramiprosate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tramiprosate inhibits the activity of KCNH2 [29]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Vitamin E

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vitamin E increases the expression of KCNH2 [83]

  Curcumin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Curcumin inhibits the activity of KCNH2 [56]

  Manidipine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Manidipine inhibits the activity of KCNH2 [56]

  Domperidone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Domperidone inhibits the activity of KCNH2 [56]

  Fasudil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fasudil inhibits the activity of KCNH2 [101] , [69]

  NVP-LAQ824

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 NVP-LAQ824 inhibits the activity of KCNH2 [70]

  MK-3102

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MK-3102 inhibits the activity of KCNH2 [112]

  BAF312

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 BAF312 inhibits the activity of KCNH2 [113]

  Bardoxolone methyl

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bardoxolone methyl inhibits the activity of KCNH2 [117]

Drug in Phase 2 Trial

  Staurosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Staurosporine inhibits the transportation of Astemizole by KCNH2 [1]

Affected Drug/Substrate

 Astemizole Modulation Type Inhibition

  PF-00734200

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PF-00734200 inhibits the activity of KCNH2 [26]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  TD-5108

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 TD-5108 inhibits the activity of KCNH2 [15]

Cell System

 Chinese hamster ovary (CHO) cells-KCNH2

  AR9281

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 AR9281 inhibits the activity of KCNH2 [30]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  HP-184

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 HP-184 blocks the activity of KCNH2 [92]

  BMS-582949

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 BMS-582949 inhibits the activity of KCNH2 [103]

  MGCD-0103

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MGCD-0103 inhibits the activity of KCNH2 [70]

  PDX-101

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PDX-101 inhibits the activity of KCNH2 [70]

  MS-275

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 SNDX-275 inhibits the activity of KCNH2 [70]

  PF-03715455

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PF-03715455 inhibits the activity of KCNH2 [107]

  Piboserod

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Piboserod inhibits the activity of KCNH2 [109]

  PF-3893787

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PF-3893787 inhibits the activity of KCNH2 [110]

  GSK239512

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 GSK239512 inhibits the activity of KCNH2 [111]

  NVP-AUY922

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 NVP-AUY922 inhibits the activity of KCNH2 [114]

  BMS-911543

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 BMS-911543 inhibits the activity of KCNH2 [115]

Drug in Phase 1/2 Trial

  CX-4945

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 CX-4945 inhibits the activity of KCNH2 [106]

  CEP-32496

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 CEP-32496 inhibits the activity of KCNH2 [108]

Drug in Phase 1 Trial

  Mibefradil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mibefradil inhibits the activity of KCNH2 [7]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Radiprodil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Radiprodil inhibits the activity of KCNH2 [31]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  2-deoxyglucose

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 2-deoxyglucose inhibits the activity of KCNH2 [76]

  Adenosine Triphosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Adenosine Triphosphate inhibits the activity of KCNH2 [76]

  Geldanamycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Geldanamycin inhibits the expression of KCNH2 [77]

  AY-27,255

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 AY-27,255 inhibits the activity of KCNH2 [41]

  Beta-cyclodextrins

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Beta-cyclodextrins inhibits the activity of KCNH2 [80]

  Naringenin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naringenin inhibits the activity of KCNH2 [81]

  Cibenzoline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cibenzoline inhibits the activity of KCNH2 [54]

  Trichostatin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Trichostatin A inhibits the expression of KCNH2 [85]

  Fingolimod Hydrochloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fingolimod Hydrochloride inhibits the activity of KCNH2 [86]

  Bromperidol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bromperidol inhibits the activity of KCNH2 [56]

  Clotiapine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clotiapine inhibits the activity of KCNH2 [56]

  Denopamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Denopamine inhibits the activity of KCNH2 [56]

  Fendiline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fendiline inhibits the activity of KCNH2 [56]

  Ipriflavone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ipriflavone inhibits the activity of KCNH2 [56]

  KB-2796

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 KB-2796 inhibits the activity of KCNH2 [56]

  M-813

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 M-813 inhibits the activity of KCNH2 [56]

  MJ-13105

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MJ-13105 inhibits the activity of KCNH2 [56]

  Pericyazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pericyazine inhibits the activity of KCNH2 [56]

  Pizotifen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pizotifen inhibits the activity of KCNH2 [56]

  Prenylamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Prenylamine inhibits the activity of KCNH2 [56]

  Quinacrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinacrine inhibits the activity of KCNH2 [56]

  Vincamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vincamine inhibits the activity of KCNH2 [56]

  Retigabine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Retigabine affects the activity of KCNH2 [89]

  Ajmaline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ajmaline inhibits the activity of KCNH2 [54]

  Sertindole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sertindole inhibits the activity of KCNH2 [54]

  Lidoflazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lidoflazine inhibits the activity of KCNH2 [56]

  Benzethonium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzethonium inhibits the activity of KCNH2 [54]

  Isoquine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Isoquine inhibits the activity of KCNH2 [93]

  Turofexorate isopropyl

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Turofexorate isopropyl inhibits the activity of KCNH2 [97]

  Temanogrel

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Temanogrel inhibits the activity of KCNH2 [100]

  MK-7246

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MK-7246 inhibits the activity of KCNH2 [105]

Drug in Preclinical Test

  Proadifen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Proadifen inhibits the activity of KCNH2 [56]

Discontinued Drug

  Fananserin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fananserin inhibits the activity of KCNH2 [19]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  PRX-00023

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PRX-00023 inhibits the activity of KCNH2 [21]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  PNU-282987

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PNU-282987 inhibits the activity of KCNH2 [22]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  YM60828

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 YM60828 inhibits the activity of KCNH2 [23]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Ronacaleret

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ronacaleret inhibits the activity of KCNH2 [95]

  GSK163090

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 GSK163090 inhibits the activity of KCNH2 [104]

Investigative Drug

  Cyclorgdfv

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclorgdfv inhibits the activity of KCNH2 [21]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Diphenyl(Piperidin-4-Yl)Methanol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diphenyl(Piperidin-4-Yl)Methanol inhibits the activity of KCNH2 [2]

  3,9-Dihydro-N-Desmethyl-N-Isopropylerythromycin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 3,9-Dihydro-N-Desmethyl-N-Isopropylerythromycin A inhibits the activity of KCNH2 [11]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Glucose

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Glucose inhibits the activity of KCNH2 [76]

  Ginsenoside Rb1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ginsenoside Rb1 affects the activity of KCNH2 [78]

  Cyamemazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyamemazine inhibits the activity of KCNH2 [82]

  Malachite green

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Malachite green inhibits the activity of KCNH2 [50]

  Aprindine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aprindine inhibits the activity of KCNH2 [56]

  Bopindolol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bopindolol inhibits the activity of KCNH2 [56]

  Isoconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Isoconazole inhibits the activity of KCNH2 [56]

  1-(1-(2-Fluorophenyl)-2-(2-(Trifluoromethoxy)Phenyl)Ethyl)Piperazine (Enantiomeric Mix)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-(1-(2-Fluorophenyl)-2-(2-(Trifluoromethoxy)Phenyl)Ethyl)Piperazine (Enantiomeric Mix) inhibits the activity of KCNH2 [91]

  1-(1-(4-Fluorophenyl)-2-(2-(Trifluoromethoxy)Phenyl)Ethyl)Piperazine (Enantiomeric Mix)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-(1-(4-Fluorophenyl)-2-(2-(Trifluoromethoxy)Phenyl)Ethyl)Piperazine (Enantiomeric Mix) inhibits the activity of KCNH2 [91]

  1-(2-(2-(Difluoromethoxy)Phenyl)-1-Phenylethyl)Piperazine (Enantiomeric Mix)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-(2-(2-(Difluoromethoxy)Phenyl)-1-Phenylethyl)Piperazine (Enantiomeric Mix) inhibits the activity of KCNH2 [91]

  Premafloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Premafloxacin inhibits the activity of KCNH2 [64]

  Triphenylmethanamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triphenylmethanamine inhibits the activity of KCNH2 [94]

  PHA-666859

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 PHA-666859 inhibits the activity of KCNH2 [98]

  1-(2,3-Dichlorophenyl)-2,2,2-Trifluoro-1-(1-(4-Fluorophenyl)-1H-Indazol-5-Yl)Ethanol (Enantiomeric Mix)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-(2,3-Dichlorophenyl)-2,2,2-Trifluoro-1-(1-(4-Fluorophenyl)-1H-Indazol-5-Yl)Ethanol (Enantiomeric Mix) inhibits the activity of KCNH2 [99]

  1-(3-Chloro-4-Fluorophenyl)-2,2,2-Trifluoro-1-(1-(4-Fluorophenyl)-1H-Indazol-5-Yl)Ethanol (Enantiomeric Mix)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-(3-Chloro-4-Fluorophenyl)-2,2,2-Trifluoro-1-(1-(4-Fluorophenyl)-1H-Indazol-5-Yl)Ethanol (Enantiomeric Mix) inhibits the activity of KCNH2 [99]

  Nifevirocn

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nifevirocn inhibits the activity of KCNH2 [102]

  Acid-activated omeprazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acid-activated omeprazole inhibits the activity of KCNH2 [69]

  GSK189254A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 GSK189254A inhibits the activity of KCNH2 [111]

  Saccharin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Saccharin inhibits the activity of KCNH2 [116]

Drug Withdrawn

  Terfenadine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Terfenadine inhibits the transportation of Astemizole by KCNH2 [1]

Affected Drug/Substrate

 Astemizole Modulation Type Inhibition

  DT Modulation 2

 Terfenadine inhibits the activity of KCNH2 [2]

  DT Modulation 3

 Terfenadine inhibits the activity of KCNH2 [3]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Astemizole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Astemizole inhibits the activity of KCNH2 [7] , [24] , [25]

Cell System

 Human embryonic kidney 293 cells (HEK293)-KCNH2

  Nimesulide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nimesulide inhibits the activity of KCNH2 [54]

  Zimeldine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zimeldine inhibits the activity of KCNH2 [54]

  Benzydamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzydamine inhibits the activity of KCNH2 [56]

  Flupenthixol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Flupenthixol inhibits the activity of KCNH2 [56]

  Niguldipine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Niguldipine inhibits the activity of KCNH2 [56]

Natural Product

  Mitragynine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mitragynine inhibits the expression of KCNH2 [88]

  Particulate Matter

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Particulate Matter increases the expression of KCNH2 [90]

Acute Toxic Substance

  Mercury

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mercury increases the expression of KCNH2 [79]

Health and Environmental Toxicant

  Butyraldehyde

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Butyraldehyde increases the expression of KCNH2 [87]

Herbicide

  Atrazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Atrazine increases the expression of KCNH2 [84]

Chemical Compound

  Pentanal

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pentanal increases the expression of KCNH2 [87]
References
1 Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety. J Med Chem. 2005 Mar 24;48(6):1725-8.
2 Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7.
3 Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist. Eur J Med Chem. 2013 Jun;64:629-37.
4 Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4633-7.
5 An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.
6 Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5303-8.
7 Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel. J Med Chem. 2007 Jun 28;50(13):2931-41.
8 Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J Med Chem. 2009 Jan 8;52(1):151-69.
9 Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
10 Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4380-4.
11 Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists: optimizing for potency and safety. J Med Chem. 2009 Nov 12;52(21):6851-9.
12 9-Dihydroerythromycins as non-antibiotic motilin receptor agonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5658-61.
13 Bioactive sulfoximines: syntheses and properties of Vioxx analogs. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4888-90.
14 Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4849-53.
15 Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6048-52.
16 Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. J Med Chem. 2013 Mar 14;56(5):1974-83.
17 Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties. ACS Med Chem Lett. 2013 Sep 22;4(11):1037-41.
18 Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors. Bioorg Med Chem. 2015 Sep 1;23(17):5881-90.
19 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem. 2002 Jan 17;45(2):492-503.
20 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
21 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J Med Chem. 2006 Jun 1;49(11):3116-35.
22 Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J Med Chem. 2006 Jul 13;49(14):4425-36.
23 Inhibitory effect of carboxylic acid group on hERG binding. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5507-12.
24 Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1834-8.
25 Astemizole Derivatives as Fluorescent Probes for hERG Potassium Channel Imaging. ACS Med Chem Lett. 2016 Jan 20;7(3):245-9.
26 (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1991-5.
27 Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7.
28 Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem. 2012 Dec 13;55(23):10644-51.
29 Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3467-9.
30 Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem. 2014 Aug 28;57(16):7016-30.
31 Discovery of orally bioavailable cyclohexanol-based NR2B-selective NMDA receptor antagonists with analgesic activity utilizing a scaffold hopping approach. Bioorg Med Chem Lett. 2017 Sep 1;27(17):4194-4198.
32 Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):29-37.
33 Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. Clin Sci (Lond). 2004 Aug;107(2):175-82.
34 Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet. 2002;17(4):374-7.
35 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6.
36 Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res. 2005 Jan;63(1):17-25.
37 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
38 Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006 Mar;316(3):1098-106.
39 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52.
40 Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels. Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1059-65.
41 Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity. J Appl Toxicol. 2007 Jan-Feb;27(1):78-85.
42 Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol. 2008 Feb;153(3):439-47.
43 Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31.
44 Effects of common antitussive drugs on the hERG potassium channel current. J Cardiovasc Pharmacol. 2008 Dec;52(6):494-9.
45 Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. J Pharmacol Sci. 2008 Dec;108(4):462-71.
46 Intracellular potassium stabilizes human ether-?go-go-related gene channels for export from endoplasmic reticulum. Mol Pharmacol. 2009 Apr;75(4):927-37.
47 Block of HERG k channel by classic histamine h(1) receptor antagonist chlorpheniramine. Korean J Physiol Pharmacol. 2009 Jun;13(3):215-20.
48 Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells. Arch Drug Inf. 2009 Sep;2(3):51-57.
49 Identification of human Ether-?go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev Technol. 2010 Dec;8(6):727-42.
50 Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicol Appl Pharmacol. 2011 May 1;252(3):250-8.
51 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
52 Arsenic trioxide induces the apoptosis of human breast cancer MCF-7 cells through activation of caspase-3 and inhibition of HERG channels. Exp Ther Med. 2011 May;2(3):481-486.
53 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
54 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94.
55 Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. Biomark Insights. 2016 Aug 24;11:113-21.
56 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895.
57 Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. Toxicol Lett. 2022 Jul 15;365:11-23.
58 Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. J Appl Toxicol. 2018 Apr;38(4):450-458.
59 Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential. Toxicol Sci. 2019 Apr 1;168(2):365-380.
60 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
61 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
62 Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
63 Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
64 The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2150-5.
65 Selenophene-containing inhibitors of type IIA bacterial topoisomerases. J Med Chem. 2011 May 12;54(9):3418-25.
66 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007 Dec 27;50(26):6450-3.
67 Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2179-85.
68 Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem. 2010 Dec 1;18(23):8150-7.
69 Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):97-101.
70 Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem. 2011 Jul 14;54(13):4752-72.
71 Optimization of propafenone analogues as antimalarial leads. J Med Chem. 2011 Nov 10;54(21):7477-85.
72 Wake-promoting agents: search for next generation modafinil: part I. Bioorg Med Chem Lett. 2012 Mar 15;22(6):2312-4.
73 Asymmetric synthesis and evaluation of a hydroxyphenylamide voltage-gated sodium channel blocker in human prostate cancer xenografts. Bioorg Med Chem. 2012 Mar 15;20(6):2180-8.
74 Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives. J Med Chem. 2015 Apr 23;58(8):3411-31.
75 Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. Eur J Med Chem. 2017 Jan 27;126:1129-1135.
76 Impairment of human ether-?go-go-related gene (HERG) K+ channel function by hypoglycemia and hyperglycemia. Similar phenotypes but different mechanisms. J Biol Chem. 2003 Mar 21;278(12):10417-26.
77 Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res. 2003 Jun 27;92(12):e87-100.
78 Modulating effect of ginseng saponins on heterologously expressed HERG currents in Xenopus oocytes. Acta Pharmacol Sin. 2005 May;26(5):551-8.
79 Microarray analysis of mercury-induced changes in gene expression in human liver carcinoma (HepG2) cells: importance in immune responses. Int J Environ Res Public Health. 2006 Jun;3(2):141-73.
80 Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay. J Cardiovasc Pharmacol. 2007 May;49(5):269-74.
81 The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology. 2008;110(3):145-52.
82 Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs. J Pharm Pharmacol. 2008 Nov;60(11):1507-13.
83 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
84 Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
85 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
86 Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation. Toxicol Appl Pharmacol. 2014 Nov 15;281(1):39-47.
87 Integrated analysis of microRNA and mRNA expression profiles highlights aldehyde-induced inflammatory responses in cells relevant for lung toxicity. Toxicology. 2015 Aug 6;334:111-21.
88 Mitragynine and its potential blocking effects on specific cardiac potassium channels. Toxicol Appl Pharmacol. 2016 Aug 15;305:22-39.
89 Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317.
90 Toxicogenomic study to identify potential signaling alterations related to nasal inflammatory damages induced by diesel exhaust particles in primary human nasal epithelial cells. Toxicol In Vitro. 2020 Dec;69:104994.
91 Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
92 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
93 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J Med Chem. 2009 Mar 12;52(5):1408-15.
94 Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
95 The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3328-32.
96 Design, synthesis, and biological evaluation of 16-substituted 4-azasteroids as tissue-selective androgen receptor modulators (SARMs). J Med Chem. 2009 Aug 13;52(15):4578-81.
97 Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. J Med Chem. 2010 Feb 25;53(4):1774-87.
98 Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2634-8.
99 5-Functionalized indazoles as glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 May 15;20(10):3017-20.
100 Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis. J Med Chem. 2010 Jun 10;53(11):4412-21.
101 Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9.
102 Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4012-4.
103 Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38 MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem. 2010 Sep 23;53(18):6629-39.
104 Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist. J Med Chem. 2010 Dec 9;53(23):8228-40.
105 Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93.
106 Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2011 Jan 27;54(2):635-54.
107 Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54(22):7797-814.
108 Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J Med Chem. 2012 Feb 9;55(3):1082-105.
109 Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands. J Med Chem. 2012 Nov 26;55(22):9446-66.
110 A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. Bioorg Med Chem Lett. 2013 May 1;23(9):2663-70.
111 Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6890-6.
112 Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.
113 Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7.
114 Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. Eur J Med Chem. 2014 Nov 24;87:765-81.
115 Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. ACS Med Chem Lett. 2015 Jul 12;6(8):850-5.
116 Saccharin Aza Bioisosteres-Synthesis and Preclinical Property Comparisons. ACS Med Chem Lett. 2017 May 1;8(6):672-677.
117 Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy. J Med Chem. 2017 Nov 9;60(21):8847-8857.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.